Cells cut up proteins, move some fragments to a loading site and place them on display molecules that T cells can inspect. Having a protein inside a cell does not guarantee its fragment is shown.
Antigen-processing machinery (APM) is the set of proteins that generate, transport and load peptides onto HLA. A common class I route has five steps. (1) The proteasome cuts intracellular proteins into fragments, which can create a useful peptide or destroy it. (2) The transporter associated with antigen processing, TAP1 with TAP2, moves peptides into the endoplasmic reticulum; Shepherd et al. (1993) showed in a cell-free system that TAP1 is part of an ATP-dependent, sequence-selective peptide translocator. (3) ERAP1 and ERAP2 trim amino acids from the front end. York et al. (2002) found that ERAP1 can enhance or limit presentation by trimming epitopes to 8 to 9 residues, and Saveanu et al. (2005) found complementary human ERAP1 and ERAP2 activity, so more expression does not universally improve display. A class I HLA heavy chain assembles with beta-2 microglobulin (B2M) and a peptide, with helpers such as tapasin. (4) Stable peptide-HLA complexes reach the surface; the peptide stays held by HLA. (5) A compatible T-cell receptor on a conventional CD8 T cell may recognise the pair; recognition is a separate gate and display alone does not show killing.
Class II HLA commonly loads peptides in vesicles that process acquired proteins. An invariant chain protects the new groove and directs it there; after cutting, a remaining fragment is exchanged for other peptides with help from HLA-DM, and conventional CD4 T cells inspect these displays. Cross-presentation lets externally acquired material reach class I. The scheme is a common route, not a rule for every peptide.
A cancer cell may keep an altered protein and still show little of its peptide, and a shared processing defect can affect several targets at once, so adding candidate peptides does not bypass the bottleneck. Low expression, gene loss and a functional defect are different findings: a weak RNA signal does not prove deletion. Interferon gamma can increase presentation machinery when its signalling pathway and the required genes are intact, and cannot replace a deleted B2M or HLA gene. Sucker et al. (2017) described melanoma lesions in which JAK1 or JAK2 defects gave interferon-gamma resistance and evolved into HLA class I negative, T-cell-resistant lesions with antigen-presentation genes silenced and no longer inducible. Zaretsky et al. (2016) found, in biopsies from patients with acquired resistance to PD-1 blockade, JAK1 or JAK2 loss of function in two of four patients and a truncating B2M mutation with lost surface class I in a third. These are melanoma observations, not treatment-benefit evidence.
Evidence layers differ. DNA sequence and copy number show gene retention or alteration but not expression or function; RNA shows sampled gene activity but not protein, assembly or display; protein staining or flow cytometry detects protein but not which peptide is shown; HLA-associated peptide recovery shows a peptide was recovered with HLA in that preparation but not its cell of origin or recognition; controlled T-cell recognition shows function against tested targets. Peptide loading can bypass processing, so rescue by supplied peptide supports a bottleneck under those conditions only. Binding prediction is not presentation, and CD4 help is not proof of CD8 tumour recognition.
In plain words · B2M supplies a light-chain protein used by class I HLA and several related complexes. A variant or RNA result alone does not establish loss of these functions.
Showing the target this term concerns: B2M.
Shares HLA allele names and typing reports, Antigen, HLA (human leukocyte antigen) and MHC and the tag education-immunology-2026-11.
Shares Epitope and the tag education-immunology-2026-11.
Shares Neoantigen candidate selection, HLA (human leukocyte antigen) and MHC.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Shares Dendritic-cell cross-presentation (cDC1), CIITA, JAK1, Antigen.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/